Table 6 FDA approved drugs/therapies regarding the microbiota in cancer therapy
From: Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy
Drug | Experimental drug | Target | Associated Microbial | Tumor type | Effect | Ref |
|---|---|---|---|---|---|---|
ADI-PEG 20 | Pegargiminase | None | Mycoplasma | Hepatocellular carcinoma | Killing the melanoma cells by activating caspase 8/10-dependent apoptotic pathways | |
BCG | BCG vaccine (Nippon BCG Seizo KK) | None | Mycobacterium bovis | Non Muscle Invasive Bladder Cancer (NMIBC) | Activation of TLR2 and TLR4 | |
Talimogene laherparepvec (T-VEC) | T-VEC | CSF | Herpes simplex virus-1 (HSV-1) | Advanced melanoma | Triggering cancer cell lysis | |
L-asparaginase | L-asparaginase | ASN | E. coli | Acute lymphoblastic leukemia | Degrading asparagine and glutamine |
